

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/707,043	11/17/2003	Richard M. Chesbrough	289-PDD-07-31 US	4168
69683 C. R. Bard, Inc	7590 12/18/2909		EXAMINER	
Bard Peripheral Vascular, Inc. WEATHERS			, ELLSWORTH	
1415 W. 3rd St PO Box 1740			ART UNIT	PAPER NUMBER
Tempe, AZ 85	5280-1740		3768	
			MAIL DATE	DELIVERY MODE
			12/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/707,043	CHESBROUGH ET AL.	
Examiner	Art Unit	
ELLSWORTH WEATHERBY	3768	

	ELLSWORTH WEATHERBY	3768	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED 02 September 2009 FAILS TO PLACE THIS	S APPLICATION IN CONDITION I	OR ALLOWANCE.	
<ol> <li>M The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following i application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	the same day as filing a Notice of eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing	date of the final rejection.		
b) A The period for reply expires on: (1) the mailing date of this Ar no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(I	iter than SIX MONTHS from the mailing	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date where been filled is the date for purposes of determining the period called under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (a) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1 ension and the corresponding amount hortened statutory period for reply origi	of the fee. The appropria inally set in the final Office	ate extension fee e action; or (2) as
The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with the property of the p	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
<u>AMENDMENTS</u>			
<ol> <li>The proposed amendment(s) filed after a final rejection, be</li> <li>They raise new issues that would require further core</li> <li>They raise the issue of new matter (see NOTE below)</li> </ol>	sideration and/or search (see NO v);	TE below);	
<ul><li>(c) ☐ They are not deemed to place the application in bett appeal; and/or</li></ul>	,		ne issues for
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	orresponding number of finally reje	ected claims.	
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (l	PTOL-324).
<ol> <li>Applicant's reply has overcome the following rejection(s):</li> </ol>			
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	owable if submitted in a separate,	timely filed amendmer	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ll be entered and an e.	xplanation of
Claim(s) objected to: Claim(s) rejected:			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea and was not earlier presented. Se	al and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a ).
<ol> <li>The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER</li> </ol>	n of the status of the claims after e	ntry is below or attach	ed.
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information Disclosure Statement(s). ( 13. Other:	PTO/SB/08) Paper No(s)		
/Long V Le/ Supervisory Patent Examiner, Art Unit 3768			
Supervisory raterit Examiner, Art Offit 3700			

Continuation of 11. does NOT place the application in condition for allowance because: Applicant alleges that present claims are allowable over the combination of Foerster '528 in view of Makower '603. Applicant's alleges that the combination of Foerster and Makower would render each other inoperable, because Foerster requires a cannula tube to be stationary while Makower requires a cannula to be movable. The Examiner notes that the 30fo/62009 Final Rejection recognized that Foerster does not teach a retractable rannula and that Makower was applied to teach that deficiency. However, the Examiner stands that a modification of the deployment means of Foerster in view of the actuated cannula of Makower free the combination inoperable. Because Foerster and Makower are within the same field of endeavor, the field of lissue marking or tragging, one of ordinary skill in the art would be aware of the various types of deployments. That is, an actuated cannula, a hydraulic, and a plunger type deployment are all well known means for the deployment of an internal medical device from an introducer device. Therefore, to change out the method of deployment of the marker coil of Foerster for a different well known deployment method would be expected from one of ordinary skill in the art in a normal effort to improve the operation of the device, in this instance, Foerster is modified by the moveable cannula and actuator of Makower. Accordingly and because Applicant has not set forth any further arouments, claims 1-4, 6-47 and 49-75 stand relected on the grounds set forth by the 90/09/2009 Final has not set forth any further arouments, claims 1-4, 6-47 and 49-75 stand relected on the grounds set forth by the 90/09/2009 Final Receiption.